Perspectives of French adolescents with ADHD and child and adolescent psychiatrists regarding methylphenidate use
- PMID: 36899043
- PMCID: PMC10006242
- DOI: 10.1038/s41598-023-30921-4
Perspectives of French adolescents with ADHD and child and adolescent psychiatrists regarding methylphenidate use
Abstract
Many studies have demonstrated the short-term efficacy and tolerability of methylphenidate treatment adolescents with attention deficit hyperactivity disorder (ADHD). Qualitative literature on this matter focused on school outcomes, long-term side effects, family conflicts, personality changes and stigmatization. Yet, no qualitative study has crossed the perspectives of child and adolescent psychiatrists (CAPs) prescribing methylphenidate and adolescents with ADHD. This French qualitative study followed the five stages IPSE-Inductive Process to analyze the Structure of lived Experience-approach. Fifteen adolescents with ADHD and 11 CAPs were interviewed. Data collection by purposive sampling continued until data saturation was reached. Data analysis, based on a descriptive and structuring procedure to determine the structure of lived experience characterized by the central axes of experience, produced two axes: (1) The process of methylphenidate prescription, highlighting how this prescription was motivated from the exterior, experienced as passive by the adolescents and required commitment from the CAPs; and (2) the perceived effects of methylphenidate treatment, in three domains: at school, in relationships and in the sense of self. Findings raised both the issues of the epistemic position and social representation of the adolescents about ADHD and methylphenidate within this specific French context, and the self-awareness and perception of the adolescents with ADHD. We conclude that these two issues need to be regularly addressed by the CAPs prescribing methylphenidate to avoid epistemic injustice and prevent the harmful effects of stigmatization.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
[Supervised off-label prescribing of methylphenidate in adult ADHD].Encephale. 2019 Feb;45(1):74-81. doi: 10.1016/j.encep.2018.05.008. Epub 2018 Aug 16. Encephale. 2019. PMID: 30122296 French.
-
Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490. Health Technol Assess. 2009. PMID: 19883527
-
Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.Arch Gen Psychiatry. 2007 Feb;64(2):218-24. doi: 10.1001/archpsyc.64.2.218. Arch Gen Psychiatry. 2007. PMID: 17283289 Clinical Trial.
-
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Paediatr Drugs. 2009. PMID: 19445548 Review.
-
Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.JAMA. 1998 Apr 8;279(14):1100-7. doi: 10.1001/jama.279.14.1100. JAMA. 1998. PMID: 9546570 Review.
References
-
- American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 5. American Psychiatric Association; 2013.
-
- Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci. Biobehav. Rev. 2021;1(128):789–818. doi: 10.1016/j.neubiorev.2021.01.022. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous